Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Course 1: Why is genomic testing important in CLL and what does it mean for patients?

Learn about the need for and importance of genomic testing in chronic lymphocytic leukemia, including the prognostic and predictive value of TP53 aberrations and IGHV mutational status.

Toby Eyre

Toby Eyre

MBChB (Hons), MRCP (UK), FRCPath (UK), MD

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Prioty Islam

Prioty Islam

MD, MSc

Memorial Sloan Kettering Cancer Center, New York, NY, United States

Matthew Davids

Matthew Davids

MD, MMSc

Dana-Farber Cancer Institute, Boston, MA, United States

Lydia  Scarfò

Lydia Scarfò

MD

Università Vita-Salute San Raffaele, Milan, Italy

3 Modules

Watch Time: 65 minutes

Published: Mar 31 2023

1 Credit

Credits Expire: Mar 31 2024

Educational Overview
OpenClose

Activity Description

This course provides an overview of why genomic testing is important in chronic lymphocytic leukemia (CLL). Participants will learn about the biology, classification, and diagnosis of CLL, key genetic lesions (including TP53 aberrations and IGHV mutational status), their prognostic/predictive value and how this impacts treatment decision making.

Learning Objectives

As a result of attending this three-part course, you will be able to:

  • Describe the significance of key biomarkers on the pathogenesis and prognosis of CLL
  • Discuss how select mutations influence metabolic pathways and the role of new targeted drugs
  • Summarize the importance of including genomic testing in the therapeutic management of patients with CLL

Target Audience

This activity has been designed to meet the educational needs of global healthcare professionals involved in the management of CLL, including general hematologists, nurses, pathologists, and pharmacists.

Content Reviewer

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Speaker Info
OpenClose
Toby Eyre

Toby Eyre

MBChB (Hons), MRCP (UK), FRCPath (UK), MD

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Dr Toby Eyre is a consultant hematologist at Oxford University Hospitals NHS Foundation Trust, Oxford, UK, specializing in the management of lymphoid malignancies with a focus on the management of patients with lymphoma and patients with chronic lymphocytic leukemia (CLL).

He completed his hematology training in the Oxford Deanery between 2010 and 2017, including an MD Doctorate Thesis in early phase trials and biomarker studies in aggressive lymphoid disease. He is an investigator on several national UK lymphoma and CLL trials has published over 100 peer-review articles and presents regularly at national and international conferences.

Dr Eyre is a core member of the low-grade lymphoma and elderly high-grade lymphoma National Cancer Research Institute (NCRI) clinical studies group and a member of the British Committee For Standards In Haematology (BCSH) guideline writing groups for various lymphoma subtypes. He is a member of the British Society of Hematology (BSH) Haemato-Oncology Task Force and the CLL Forum executive committee. He also has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education.

Prioty Islam

Prioty Islam

MD, MSc

Memorial Sloan Kettering Cancer Center, New York, NY, United States

Dr Prioty Islam is a medical oncologist specializing in chronic lymphoid and myeloid neoplasms, including chronic lymphocytic leukemia (CLL), at Memoria Sloan Kettering Cancer Center in New York City, New York.

She received her medical degree at the University of Pennsylvania and completed training in internal medicine at Emory University followed by a Hematology and Oncology fellowship at Duke University. Dr Islam is passionate about conducting clinical research to improve the care of CLL, and is actively involved in designing, leading, and enrolling patients to clinical trials at MSKCC.

Matthew Davids

Matthew Davids

MD, MMSc

Dana-Farber Cancer Institute, Boston, MA, United States

After obtaining an A.B. cum laude in chemistry at Harvard College, Dr. Davids completed his M.D. cum laude at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (M.M.S.c.) at Harvard Medical School. He is an attending physician in the Division of Lymphoma, where he serves as the Director of Clinical Research, as well as Associate Director of the CLL Center. He is also an Associate Professor of Medicine at Harvard Medical School, and attends on the inpatient hematologic malignancies service at Brigham and Women’s Hospital.

Dr. Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.

Lydia  Scarfò

Lydia Scarfò

MD

Università Vita-Salute San Raffaele, Milan, Italy

Dr Lydia Scarfò, is a Physician Scientist at the B-cell neoplasia Unit and an Assistant Professor at Università Vita-Salute San Raffaele, Milano, Italy.

She received a degree in Medicine and Surgery from the University of Ferrara, Ferrara, Italy, in 2006, later specializing in hematology (2012) and internal medicine (2017).

Dr Scarfò joined the San Raffaele Scientific Institute, Milan, Italy in 2012, and is now Assistant Professor in Internal Medicine at Università Vita-Salute San Raffaele.

She is involved in the CLL out-patient clinic (Strategic Research Program on CLL), which is dedicated to the management and treatment of patients with CLL, including the design and conduct of clinical trials.

Dr Scarfò is currently a co-investigator in over 20 clinical trials in CLL and related disorders, including Phase 1 studies; she is a principal investigator in a Phase 3 trial for first-line treatment in follicular lymphoma.

She successfully completed the Clinical Research Training in Hematology (CRTH, 2016-2017), promoted by the European Hematology Association (EHA).

Her fields of research include:

  • Prognostic and predictive factors in chronic lymphocytic leukemia (CLL)​
  • Pre-neoplastic conditions associated with B-cell lymphoproliferative disorders, e.g. monoclonal B-cell lymphocytosis (MBL)​
  • Mechanisms of resistance to novel targeted agents​
  • Measurable residual disease (MRD) and design of clinical trials based on MRD-guided strategies
Evaluation & Accreditation
OpenClose
CME Accreditation Type
ACCME - Amedco, see accreditation statement below.
CME Credits
1 CME credits

Requirement for Successful Completion

To complete this activity and obtain CME credits, participants must:

(1) complete the educational activity online, and;
(2) complete the post-test and activity evaluation.

Participants must receive a minimum score of 80% on the post-test.

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Method Participation
There are no fees to participate in this activity.
Estimated Completion Time
65 minutes
Disclosures & Disclaimers
OpenClose

Disclosure Statement

The opinions expressed in this educational activity are those of the faculty, and do not necessarily represent the views of Magdalen Medical Publishing. This educational activity is intended to supplement existing knowledge, published information, and practice guidelines. Participants in this educational activity should critically appraise the information presented and draw conclusions only after careful consideration of all other available scientific information.

Unapproved products or unapproved uses of approved products may be discussed by the faculty and these situations may reflect the approval status in one or more jurisdictions. Mention of these unapproved products or unapproved uses in this activity should not be considered an endorsement of these products or practices. For this e-learning course, speaker disclosures have been submitted to the accrediting body, Amedco; all speakers have received an honorarium from MMP for their participation in this activity. All educational materials have been reviewed for fair balance, scientific objectivity and appropriate levels of evidence.

Acknowledgement of Financial Commercial Support

This course is supported by medical educational support from Janssen Pharmaceuticals (a Johnson & Johnson Company) and AstraZeneca. The supporter has no influence over the production of the content.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Disclosure of Conflict of Interest

Each individual in a position to control the content disclosed to Amedco all relevant financial relationships. All of these relationships were treated as a conflict of interest and have been resolved to ensure the content is un-biased.

Technical Support
OpenClose
Course Provider
Magdalen Medical Publishing
Contact Information

If you are experiencing technical difficulties, please contact [email protected] and we will get back to you as soon as possible.

Hardware & Software Requirements

This module requires the participant to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS.

Functional sound capabilities are also required as some course media may include audio content.

How to Get Your Certificate

  1. Watch all the Modules and complete the post course assessment with a score of 80% or over
  2. Click on the complete course button
  3. Evaluate the course 
  4. Print, download, or save your certificate for your records
  5. If you need help, please contact [email protected]

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and The Video Journal of Hematological Oncology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS (ACCME) CREDIT DESIGNATION STATEMENT 

Amedco LLC designates this material for a maximum of 1.00 AMA PRA Category 1 Credits™ for physicians.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACKNOWLEDGEMENT OF FINANCIAL COMMERCIAL SUPPORT

This course is supported by medical educational support from Janssen Pharmaceuticals (a Johnson & Johnson Company) and AstraZeneca. The supporter has no influence over the production of the content.